AEIRTEC LTD Information

Aeirtec has reached the phase 1 development validation stage of a novel proteomics assay platform before beta testing. The phase 1 platform will enable 150 analyte multiplexing, incorporating Aeirtec's patented curve fitting equations generating very high assay senstivity and 5 log dynamic range; combined with Aeirtec's patent-pending plate construction for fluidics free ELISA assay handling simplicity. The Phase 2 development in progress will bring the multilexing capacity to >1000. This advance in proteomics simplicity was driven by Aeirtec's 2 decades of external system use in delivering biomarker multiplexing in cliincal studies. Contact: Stephen Kilfeather on Linkedin or skilfeather@aeirtec.com